Sichuan Hexie Shuangma (SHE:000935) subsidiary Hubei Jianxiang obtained a good manufacturing practice certificate, valid until July 31, 2028, from Russia's industry and trade ministry.
The certification follows a successful on-site inspection in late July and early August 2025, covering the production of tirzepatide active pharmaceutical ingredient, according to a Tuesday filing with the Shenzhen bourse.
Tirzepatide is used to treat type 2 diabetes and for weight loss.
Shares of the company closed 1% lower Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments